Nanox (NASDAQ: NNOX) has signed a distribution agreement with SOLME RC, S.A., a Costa Rica-based medical equipment distributor, to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement positions Nanox to enter its third Latin American market this year, following Argentina and Peru, signaling a strategic push into regions where advanced imaging infrastructure is often limited.
Under the agreement, SOLME will oversee marketing, distribution, installation, training, and ongoing technical support in Costa Rica. SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services. This relationship could facilitate adoption within the public healthcare system, which serves a significant portion of the population. Commercialization will follow applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration. This phased approach allows for clinical validation and operational adjustments before broader deployment.
The deal matters because it highlights Nanox's ability to execute its global expansion strategy despite regulatory and logistical hurdles. By partnering with an established local distributor that already supplies the CCSS, Nanox gains a direct channel into Costa Rica's public health system. The proof-of-concept period is particularly important: it enables Nanox to demonstrate the Nanox.ARC's clinical utility and cost-effectiveness in a real-world setting, which could accelerate full registration and subsequent sales. Success in Costa Rica could also serve as a reference for other markets in the region, where similar public procurement processes exist.
Nanox aims to drive the world's transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform. The company combines affordable imaging hardware, AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. The Nanox ecosystem includes the Nanox.ARC, a cost-effective 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
For investors, the Costa Rica agreement represents tangible progress in Nanox's commercialization efforts. The company's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox seeks to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. The latest news and updates relating to NNOX are available in the company's newsroom at https://ibn.fm/NNOX.
As Nanox continues to expand in Latin America, the Costa Rica agreement could pave the way for additional contracts in the region and beyond. The company's ability to navigate regulatory processes and secure partnerships with established distributors will be critical to its long-term success. For now, the deal underscores Nanox's commitment to making advanced medical imaging more accessible worldwide, a goal that could have far-reaching implications for preventive care and patient outcomes.
